Clinical trials: Cancer, Advanced
Neoplasms, Solid Tumors
A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)
This is a Phase 1/1B, non-randomized, open-label, dose-escalation study of robatumumab (SCH 717454, MK-7454) administered in combination with chemotherapy in pediatric participants with solid tumors, to be conducted in…
- Conditions
- Neoplasms, Solid Tumors, Bone Cancer, Kidney Tumor
- Trial name
- NCT00960063
- Testing
- Temozolomide, Vincristine, Ifosfamide
- Volunteers
- 4 people
- Sponsor
- Merck Sharp & Dohme LLC
Locally Advanced Pancreatic Carcinoma, Prostate Cancer
Expanded Access to NanoPac
NanOlogy may consider offering expanded access to NanoPac for patients who do not meet the enrollment criteria of clinical trials in progress.
- Conditions
- Locally Advanced Pancreatic Carcinoma, Prostate Cancer, Lung Cancer
- Trial name
- NCT03756311
- Testing
- NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension
- Sponsor
- NanOlogy, LLC
Soft Tissue Sarcoma, Bone Sarcoma
SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas
The purpose of this study is to determine the efficacy of pembrolizumab in patients with advanced sarcomas.
- Trial name
- NCT02301039
- Testing
- Pembrolizumab
- Where
- 12 sites in United States
- Volunteers
- 144 people
- Sponsor
- Sarcoma Alliance for Research through Collaboration
Breast Cancer, Breast Neoplasms
Combination Chemotherapy (FLAC) Combined With Granulocyte-Macrophage Colony Stimulating Factor in Locally Advanced and Metastatic Breast Cancer
To evaluate a dose intensive chemotherapy regimen for the treatment of locally advanced and metastatic breast cancer using granulocyte-macrophage colony-stimulating factor (GM-CSF) to ameliorate chemotherapy-induced toxicity.
- Trial name
- NCT00001239
- Testing
- FLAC with GM-CSF
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- National Cancer Institute (NCI)
Hodgkin Lymphoma
Study Comparing ABVD vs BEACOPP in Advanced Hodgkin's Lymphoma
The choice of a preferred first-line treatment requires balancing the desire for optimal disease control with the occurrence of early and late treatment-related effects.
- Trial name
- NCT01251107
- Testing
- Bleomycin, Etoposide, Doxorubicin
- Where
- Italy
- Volunteers
- 331 people
- Sponsor
- Fondazione Michelangelo
Advanced Solid Tumors
Dose-finding Study of CAELYXTM and RAD001 in Patients With Advanced Solid Tumors
This is a dose finding, open-label, uncontrolled, dose-escalation trial to determine the Maximum Tolerated Dose (MTD) and the Recommended Dose (RD) of the combination RAD001 (escalating daily dose) and CaelyxTM (fixed dose) to…
- Trial name
- NCT01148628
- Testing
- RAD 001 in combination with Caelyx
- Where
- 3 sites in Italy, Switzerland
- Volunteers
- 54 people
- Sponsor
- Southern Europe New Drug Organization
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract
RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of the tumor cells and slow the growth of cancer of the urinary tract.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00014144
- Testing
- gefitinib
- Where
- 95 sites in United States
- Volunteers
- 31 people
- Sponsor
- SWOG Cancer Research Network
Adult Rhabdomyosarcoma, Childhood Alveolar Rhabdomyosarcoma
Biomarkers in Patients With Advanced Rhabdomyosarcoma
This research trial studies tumor tissue to identify important proteins and biomarkers from patients with rhabdomyosarcoma that has spread to other places in the body and usually cannot be cured or controlled with treatment.
- Conditions
- Adult Rhabdomyosarcoma, Childhood Alveolar Rhabdomyosarcoma, Childhood Embryonal Rhabdomyosarcoma, Previously Treated Childhood Rhabdomyosarcoma
- Trial name
- NCT01668095
- Testing
- Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Children's Oncology Group
Neuroblastoma
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
A prospective open label, multicenter study to evaluate the feasibility and acute toxicity of using molecularly guided therapy in combination with standard therapy followed by a Randomized Controlled Trial of standard…
- Trial name
- PEDS-PLAN (NCT02559778)
- Testing
- Ceritinib, dasatinib, sorafenib
- Where
- 28 sites in United States, Canada
- Volunteers
- 500 people
- Sponsor
- Giselle Sholler
Unresectable or Metastatic Melanoma or Advanced Solid Tumors, Melanoma
A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors
This study aims to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of APG-115, an MDM2 inhibitor, either alone or in combination with pembrolizumab, a programmed cell death protein-1 (PD-1) inhibitor…
- Conditions
- Unresectable or Metastatic Melanoma or Advanced Solid Tumors, Melanoma, Uveal Melanoma, P53 Mutation
- Trial name
- NCT03611868
- Testing
- Phase 1b: APG-115+pembrolizumab
- Where
- 21 sites in United States, Australia
- Volunteers
- 230 people
- Sponsor
- Ascentage Pharma Group Inc.
Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma
Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer
Phase I trial to study the effectiveness of paclitaxel, cisplatin, and topotecan with or without filgrastim in treating patients who have newly diagnosed stage III or stage IV epithelial ovarian cancer.
- Conditions
- Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mixed Epithelial Carcinoma
- Trial name
- NCT00002913
- Testing
- paclitaxel, cisplatin, topotecan hydrochloride
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Non Small Cell Lung Cancer
An Observational Study to Evaluate AZD9291 Treatment in Patients With T790M Positive Non-small Cell Lung Cancer
AZD9291 Early Access Program (EAP) was available in Taiwan during October 2015 to September 2016, a time period before the approval of AZD9291, to supply the unlicensed AZD9291 for the NSCLC patients who received at least one…
- Trial name
- NCT03457220
- Where
- 7 sites in Taiwan
- Volunteers
- 423 people
- Sponsor
- AstraZeneca
Cervical Cancer, Vaginal Cancer
Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cervical or Vaginal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of paclitaxel in treating patients with advanced…
- Trial name
- NCT00002562
- Testing
- paclitaxel
- Where
- 50 sites in United States
- Volunteers
- 25 people
- Sponsor
- Gynecologic Oncology Group
Sarcoma, Myxofibrosarcoma
A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg
The purpose of this study is to find out whether giving the study drug pembrolizumab in combination with the chemotherapy drugs melphalan and dactinomycin, delivered directly to the affected arm or leg using a technique called…
- Conditions
- Sarcoma, Myxofibrosarcoma, Undifferentiated Pleomorphic Sarcoma, Alveolar Soft Part Sarcoma
- Trial name
- NCT04332874
- Testing
- Isolated Limb Infusion, Pembrolizumab, infusion of melphalan and dactinomycin
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cervical Cancer
Single Application Brachytherapy in Cervical Cancer
The purpose of the study is to evaluate safety and feasibility of single brachytherapy application with dose delivery in multiple fractions.
- Trial name
- NCT03110497
- Testing
- Single application multi-fraction brachytherapy
- Where
- India
- Volunteers
- 40 people
- Sponsor
- Tata Memorial Hospital
Carcinoma, Renal Cell
Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma
This treatment protocol allows doctors to treat advanced kidney cancer with an investigational drug called sorafenib, BAY43-9006, which is being studied in clinical trials for kidney cancer and other kinds of cancer.
- Trial name
- NCT00111020
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- 320 sites in United States, Canada
- Volunteers
- 2,567 people
- Sponsor
- Bayer
Gastric Cancer, Neoadjuvant Chemotherapy
The Analysis of Immuno-Nutrition Index in Advanced Gastric Cancer Receiving Preoperative Treatments
Based on multiple studies, the immune (systemic inflammation) and nutrition index were correlated with short- and long-term prognosis for gastric cancer.
- Conditions
- Gastric Cancer, Neoadjuvant Chemotherapy, Neoadjuvant Chemoradiotherapy, Systemic Inflammatory Response Syndrome (SIRS)
- Trial name
- NCT03493880
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Peking University
Lymphoma
Non-Myeloablative Allogeneic Stem Cell Transplantation
1. To determine the safety and efficacy of non-myeloablative allogeneic stem cell transplantation using rituximab, cyclophosphamide, fludarabine as a preparative regimen for patients with advanced or recurrent mantle cell…
- Trial name
- NCT00525876
- Testing
- Cyclophosphamide, Fludarabine, Rituximab
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Cancers
Quantitation of Left Ventricular Ejection Fraction as Part of F-18 FDG Whole Body PET/CT Scans For Tumor Staging
Primary Objective: Evaluate the agreement between radionuclide ventriculography (RNV) and gated F-18 fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) in calculating left ventricular ejection…
- Trial name
- NCT00499382
- Testing
- Nuclear Medicine Cardiac Scan, PET/CT Cardiac Scan
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- M.D. Anderson Cancer Center
Ewing Sarcoma, PEComa
Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers
This study investigates the safety/toxicity and potential anti-tumor activity of sequential administration of nivolumab and escalating doses of the mammalian target of rapamycin (mTOR) inhibitor nab-rapamycin (ABI-009) in…
- Conditions
- Ewing Sarcoma, PEComa, Epithelioid Sarcoma, Desmoid Tumor
- Trial name
- NCT03190174
- Testing
- Nab-Rapamycin, Nivolumab
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Sarcoma Oncology Research Center, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.